胰高血糖素样肽-1，作为一种“肠促胰素”，对胰岛β细胞具有多方面积极的影响。它可刺

激胰岛β细胞分泌胰岛素，促进它的增殖分化再生并抑制其凋亡，在糖尿病的治疗中有很好的应用前景

。

Glucagon-like peptide-1，as one of “incretins”，is beneficial to pancreatic

β-cells. It can enhance insulin secretion, proliferation ，differiention ，regeneration 

and inhibit the apoptosis of pancreatic β-cells. So it has promising prospects for

diabetes mellitus treatment.

［1］Dupre J, Ross SA, Watson D,et al. Stimulation of insulin secretion by gastric

inhibitory polypeptide in man ［J］.J Clin Endocrinol Metab,1973,37（5）:826-828.
［2］Edholm T, Cejvan K, Abdel-Halim SM,et al.The incretin hormones GIP and GLP-1 in

diabetic rats: effects on insulin secretion and small bowel motility ［J］.

Neurogastroenterol Motil, 2009,21(3):313-321.
［3］Vilsbll T, Brock B, Perrild H，et al.Liraglutide, a once-daily human GLP-1

analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion

during hyperglycaemia in patients with Type 2 diabetes mellitus ［J］. Diabet Med,2008,25

(2):152-156.
［4］Behme MT, Dupré J, McDonald TJ. Glucagon-like peptide 1 improved glycemic control in

Type 1 diabetes ［J］.BMC Endocr Disord,2003,3(1):3.
［5］Kendall DM,Riddle MC,Rosenstock J,et al.Effects of exenatide(exendin4) on glycemic

control over 30 weeks in patients with Type 2 diabetes treated with metformin and a

sulfonylurea［J］. Diabetes Care,2005,28（5）:1083-1091.
［6］Gromada J, Ding WG, Barg S, et al. Multisite regulation of insulin secretion by

cAMP-increasing agonists: evidence that glucagon-like peptide 1 and glucagon act via

distinct receptors ［J］.Pflugers Arch,1997,434（5）:515-524.
［7］Lin YF, Jan YN, Jan LY. Regulation of ATP-sensitive potassium channel function by

protein kinase A-mediated phosphorylation in transfected HEK293 cells ［J］.EMBO J,2000,19

（5）:942-955.
 ［8］MacDonald PE, El-Kholy W, Riedel MJ,et al.The multiple actions of GLP-1 on the

process of glucose-stimulated insulin secretion ［J］.Diabetes,2002,51（3）:S434-S442.
［9］Holz GG. New insights concerning the glucose-dependent insulin secretagogue action of

glucagon-like peptide-1 in pancreatic beta-cells［J］.Horm Metab Res,2004,36(11-12):787-

794.
［10］Shigeto M, Katsura M, Matsuda M, et al. Low, but physiological, concentration of

GLP-1 stimulates insulin secretion independent of the cAMP-dependent protein kinase

pathway［J］.J Pharmacol Sci, 2008,108(3):274-279.
［11］Garber A, Henry R, Ratner R,et al. Liraglutide versus glimepiride monotherapy for

Type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-

treatment trial ［J］.Lancet,2009,373(9662):438-439.
［12］ Mauricio D, Mandrup-Poulsen T.Apoptosis and the pathogenesis of IDDM:a question of

life and death ［J］.Diabetes,1998,47（10）:1537-1543.
 ［13］ Maedler K, Spinas GA, Dyntar D,et al.Distinct effects of saturated and

monounsaturated fatty acids on β-cell turnover and function［J］.Diabetes,2001,50(1):69-

76.
［14］ Bregenholt S, Mldrup A, Blume N,et al.The long-acting glucagon-like peptide-1

analogue,liraglutide,inhibits β-cell apoptosis in vitro［J］.Biochem Biophys Res Commun,

2005,330(2):577-584.
［15］ Li Y, Hansotia T,Yusta B,et al.Glucagon-like peptide-1 receptor signaling modulates

β-cell apoptosis［J］.J Biol Chem, 2003,278（1）:471-478.
［16］Li L, El-Kholy W, Rhodes CJ, et al.Glucagon-like peptide-1 protects beta cells from

cytokine-induced apoptosis and necrosis: role of protein kinase B

［J］.Diabetologia,2005,48(7):1339-1349.
［17］Ferdaoussi M, Abdelli S, Yang JY，et al. Exendin-4 protects beta-cells from

interleukin-1 beta-induced apoptosis by interfering with the c-Jun NH2-terminal kinase

pathway［J］.Diabetes, 2008,57(5):1205-1215.
 ［18］刘礼斌，王燕萍，潘晓东，等.Exendin-4体外通过抑制NF-Kapppa B-iNOS-NO信号心减轻氧化诱

导的小鼠MIN6胰岛β细胞凋亡［J］.药学学报，2008,43(7):690-694.
LIU Libin,WANG Yanping，PAN Xiaodong，et al.Exendin-4 protected murine MIN6 pancreatic

beta-cells from exidative stress-induced apoptosis via down-regulation of NF-Kapppa B-

iNos-No pathway［J］.Acta Pharmaceutical Sinica, 2008,43(7):690-694.
［19］Farilla L, Bulotta A, Hirshberg B,et al.Glucagon-like peptide 1 inhibits cell

apoptosis and improves glucose responsiveness of freshly isolated human islets

［J］.Endocrinology, 2003,144(12):5149-5158.
［20］Tews D, Werner U, Eckel J. Enhanced protection against cytokine- and fatty acid-

induced apoptosis in pancreatic beta cells by combined treatment with glucagon-like

peptide-1 receptor agonists and insulin analogues ［J］.Horm Metab Res,2008,40(3):172-180.
［21］ Stoffers DA, Kieffer TJ, Hussain MA,et al.Insulinotropic glucagon-like peptide 1

agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in

mouse pancreas ［J］.Diabetes,2000,49（5）:741-748.
［22］Jonsson J, Carlsson L, Edlund T, et al.Insulin-promoter  factor 1 is required for

pancreas development in mice ［J］.Nature,1994,371(6498):606-609.
 ［23］Hui H, Perfetti R. Pancreas duodenum homeobox-1 regulates pancreas development

during embryogenesis and islet cell function in adulthood ［J］.Eur J Endocrinol,2002,146

（2）:129-141.
［24］Stoffers DA, Ferrer J, Clarke WL, et al. Early-onset type-II diabetes mellitus

(MODY4) linked to IPF1 ［J］. Nat Genet,1997,17（2）:138-139.
［25］Feanny MA, Fagan SP, Ballian N,et al.PDX-1 expression is associated with islet

proliferation in vitro and in vivo ［J］.J Surg Res,2008,144(1):8-16.
 ［26］Movassat J, Beattie GM, Lopez AD, et al. Exendin 4 up-regulates expression of PDX 1

and hastens differentiation and maturation of human fetal pancreatic cells ［J］.J Clin

Endocrinol Metab,2002,87（10）:4775-4781.
［27］Li L, Lili R, Hui Q，et al. Combination of GLP-1 and sodium butyrate promote

differentiation of pancreatic progenitor cells into insulin-producing cells ［J］.Tissue

Cell,2008,40(6):437-445.
［28］Kang HM, Kim J, Park S，et al.Insulin-secreting cells from human eyelid-derived stem

cells alleviate Type I diabetes in immunocompetent mice［J］.Stem Cells,2009,27(8):1999-

2008.
［29］Zhang J, Tokui Y, Yamagata K, et al.Continuous stimulation of human glucagon-like

peptide-1 (7-36) amide in a mouse model (NOD) delays onset of autoimmune Type 1 diabetes［

J］.Diabetologia, 2007,50(9):1900-1909.
［30］Tourrel C, Bailbe D, Meile MJ, et al. Glucagon-like peptide-1 and exendin-4

stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in

persistently improved glucose homeostasis at adult age［J］.Diabetes,2001,50（7）: 1562-

1570.
［31］Tourrel C, Bailbe D, Lacorne M, et al.Persistent improvement of Type 2 diabetes in

the Goto-Kakizaki rat model by expansion of the β-cell mass during the prediabetic period

with glucagon-like peptide-1 or exendin-4 ［J］.Diabetes,2002, 51（5）:1443-1452.
［32］Susini S, Roche E, Prentki M, et al. Glucose and glucoincretin peptides synergize to

induce c-fos, c-jun, junB, zif-268, and nur-77 gene expression in pancreatic beta(INS-1)

cells ［J］.FASEB J,1998,12（12）:1173-1182.
［33］Buteau J, Roduit R, Susini S, et al. Glucagon-like peptide-1 promotes DNA synthesis,

activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and

duodenal homeobox gene 1 (PDX-1) DNA binding activity in (INS-1) β- cells

［J］.Diabetologia,1999,42（7）:856-864.
［34］Wang Q,Li L,Xu E,et al. Glucagon-like peptide-1 regulates proliferation and

apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells

［J］.Diabetologia,2004,47(3):478-487.
［35］Buteau J, Foisy S, Joly E,et al.Glucagon-like peptide 1 induces pancreatic beta-cell

proliferation via transactivation of the epidermal growth factor receptor［J］.Diabetes,

2003,52（1）:124-132.
［36］Liu Z, Habener JF. Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt

signaling enhances pancreatic beta cell proliferation ［J］.J Biol Chem,2008,283(13):8723

-8735.
［37］Shu L, Matveyenko AV, Kerr-Conte J,et al.Decreased TCF7L2 protein levels in Type 2

diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired

beta-cell function.［J］.Hum Mol Genet, 2009,18(13):2388-2399.